Emergent BioSolutions (EBS) Current Deferred Revenue (2010 - 2026)

Emergent BioSolutions' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $17.6 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.0 million, changed N/A from the prior year.
• Current Deferred Revenue climbed to $17.6 million in Q1 2026 per EBS's latest filing, from $5.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $17.6 million in Q1 2026 and bottomed at $5.0 million in Q4 2025.
• The 3-year median for Current Deferred Revenue is $15.9 million (2022), against an average of $12.8 million.
• Biggest YoY gain for Current Deferred Revenue was 85.9% in 2022; the steepest drop was 85.9% in 2022.
• Year by year, Current Deferred Revenue stood at $15.9 million in 2022, then plunged by 68.55% to $5.0 million in 2025, then jumped by 252.0% to $17.6 million in 2026.
• Per Business Quant, the three latest EBS Current Deferred Revenue figures stand at $17.6 million (Q1 2026), $5.0 million (Q4 2025), and $15.9 million (Q1 2022).